Tilray | TRLY - Net Income

Stock Price
10.82
Daily Change
-0.03 -0.28%
Monthly
-10.13%
Yearly
849.12%
Q1 Forecast
10.37

Tilray reported $-44.93M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acasti Pharma USD -938K 2.42M Sep/2025
Akebia Therapeutics USD 6.11M 28.92M Mar/2025
Alaunos Therapeutics USD -1.16M 417K Sep/2025
Aurora Cannabis CAD -51.47M 36.26M Sep/2025
Avita Medical AUD -9.92M 1.67M Jun/2025
Canopy Growth CAD -1.64M 39.89M Sep/2025
Cronos Group USD -25.96M 13.75M Sep/2025
Dianthus Therapeutics USD -36.76M 5.13M Sep/2025
Divis Laboratories Ltd INR 5.83B 1.06B Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
IQVIA Holdings USD 514M 183M Dec/2025
Knight Therapeutics CAD 85K 2.03M Sep/2024
Moderna USD -200M 625M Sep/2025
Organigram Holdings CAD -37.96M 31.67M Sep/2025
Organon & Co USD 160M 15M Sep/2025
Revvity USD 98.36M 51.71M Dec/2025
Tectonic Therapeutic USD -19.04M 940K Sep/2025
Tilray USD -44.93M 44.61M Sep/2025
Viatris USD -128.2M 123.6M Sep/2025
Xeris Pharmaceuticals USD 621K 2.55M Sep/2025